ArticleScience translational medicine2017
Combined OX40L and mTOR blockade controls effector T cell activation while preserving T
Abstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 80 citations in OpenAlex.
- Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.Clinical pharmacology and therapeutics · 2022Trial
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- Induction of Clinical Operational Tolerance Through Immunosuppression Minimization: Less Is More?Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy.Frontiers in medicine · 2026Review
- Combination antagonism of TNF superfamily signaling for T cell immunosuppression.Frontiers in immunology · 2026Article
- Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.Transplantation · 2025Review
- Article
- Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease.Science translational medicine · 2025Article
- A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab.Dermatology and therapy · 2024Review
- Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases.The Journal of experimental medicine · 2024Review
- Review
- Human OX40L-CAR-TScience translational medicine · 2024Article
- Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models.Journal for immunotherapy of cancer · 2024Article
- Spatial multiomics of arterial regions from cardiac allograft vasculopathy rejected grafts reveal novel insights into the pathogenesis of chronic antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.Cell communication and signaling : CCS · 2024Review
- OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.American journal of clinical dermatology · 2024Review
- Molecular Imaging of Acute Graft-Versus-Host Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives.Life (Basel, Switzerland) · 2023Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 3 institutions in 2 countries.
Victor TkachevBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA. leslie.kean@seattlechildrens.org vtkach@uw.edu.ORCID http://orcid.org/0000-0001-6011-0576
Scott N FurlanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Benjamin WatkinsBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Daniel J HuntBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Hengqi Betty ZhengBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.ORCID http://orcid.org/0000-0003-0575-6475
Angela Panoskaltsis-MortariDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.ORCID http://orcid.org/0000-0003-1802-1785
Kayla BetzBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Melanie BrownBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
John B SchellBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.ORCID http://orcid.org/0000-0001-6707-7051
Katie ZeleskiBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.ORCID http://orcid.org/0000-0001-5319-0985
Alison YuBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.ORCID http://orcid.org/0000-0003-4903-102X
Ian KirbyKymab Ltd., Cambridge CB22 3AT, UK.
Sarah CooleyDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Jeffrey S MillerDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.ORCID http://orcid.org/0000-0002-9608-9841
Duncan CassonKymab Ltd., Cambridge CB22 3AT, UK.ORCID http://orcid.org/0000-0001-6418-6455
Phil Bland-WardKymab Ltd., Cambridge CB22 3AT, UK.
Leslie S KeanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA 98101, USA. leslie.kean@seattlechildrens.org vtkach@uw.edu.ORCID http://orcid.org/0000-0003-0475-3926
Seattle Children's Hospital · USUniversity of Minnesota Medical Center · USKymab (United Kingdom) · GB
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4MTransplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1MTrial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME · 2009 to 2019
$17.5MNovel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MIN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MT CELL TARGETING FOR GVHDR37HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R. · 1998 to 2007
$3.2MNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS P30 CA077598NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R37 HL056067NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI034495NIAID NIH HHS R37 AI034495NIAID NIH HHS U19 AI051731
Abstract
A critical question facing the field of transplantation is how to control effector T cell (T
Indexed as
Hematopoietic Stem Cell TransplantationCD11c AntigenCD3 ComplexCell ProliferationCytokinesDendritic CellsDrug SynergismGraft vs Host DiseaseHumansImmunityLymphocyte ActivationMyeloid CellsOX40 LigandSignal TransductionSirolimusSurvival AnalysisCD11c AntigenCD3 ComplexCytokinesOX40 LigandSirolimusTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.